Zacks: Analysts Anticipate Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Will Post Earnings of -$1.69 Per Share

Analysts forecast that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) will post ($1.69) earnings per share for the current quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Alnylam Pharmaceuticals’ earnings, with estimates ranging from ($2.02) to ($1.13). Alnylam Pharmaceuticals posted earnings per share of ($1.61) during the same quarter last year, which suggests a negative year-over-year growth rate of 5%. The business is expected to report its next earnings results on Monday, January 1st.

On average, analysts expect that Alnylam Pharmaceuticals will report full year earnings of ($6.94) per share for the current financial year, with EPS estimates ranging from ($8.52) to ($5.19). For the next year, analysts anticipate that the business will post earnings of ($3.22) per share, with EPS estimates ranging from ($8.73) to $0.35. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last issued its earnings results on Thursday, April 28th. The biopharmaceutical company reported ($2.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.84) by ($0.16). The business had revenue of $186.90 million during the quarter, compared to the consensus estimate of $242.82 million. Alnylam Pharmaceuticals had a negative net margin of 101.46% and a negative return on equity of 121.90%. The firm’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period last year, the business posted ($1.71) EPS.

Several brokerages have commented on ALNY. Chardan Capital reiterated a “buy” rating and set a $200.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, February 11th. Guggenheim raised Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $170.00 target price on the stock in a research note on Thursday, February 3rd. Oppenheimer restated an “outperform” rating and set a $205.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 6th. Bank of America reaffirmed a “buy” rating and issued a $211.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, January 3rd. Finally, StockNews.com assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $219.76.

Shares of ALNY stock opened at $139.05 on Tuesday. Alnylam Pharmaceuticals has a 52-week low of $125.00 and a 52-week high of $212.00. The stock has a market cap of $16.79 billion, a PE ratio of -18.56 and a beta of 0.85. The company has a debt-to-equity ratio of 1.15, a quick ratio of 3.91 and a current ratio of 4.04. The firm’s 50 day moving average price is $160.12 and its two-hundred day moving average price is $165.56.

In other news, Director Steven M. Paul sold 15,000 shares of the business’s stock in a transaction dated Friday, April 1st. The stock was sold at an average price of $170.69, for a total value of $2,560,350.00. Following the sale, the director now directly owns 1,000 shares in the company, valued at $170,690. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.40% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in ALNY. UMB Bank N A MO bought a new position in shares of Alnylam Pharmaceuticals in the first quarter valued at $28,000. FSB Premier Wealth Management Inc. bought a new position in Alnylam Pharmaceuticals during the fourth quarter worth about $30,000. KRS Capital Management LLC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth approximately $33,000. Achmea Investment Management B.V. bought a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $35,000. Finally, HM Payson & Co. acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $37,000. Institutional investors own 92.39% of the company’s stock.

Alnylam Pharmaceuticals Company Profile (Get Rating)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Read More